Cepharanthin, a biscoclaurine alkaloid, prevents destruction of acinar tissues in marine Sjögren's syndrome

Journal of Rheumatology

Volumn 33, Issue 5, 2006, Pages 912-920

  Azuma, Masayuki ^a,b   Ashida, Yuki ^a,b   Tamatani, Tetsuya ^a,b   Motegi, Katsumi ^a,b   Takamaru, Natsumi ^a,b   Ishimaru, Naozumi ^a,c   Hayashi, Yoshio ^a,c   Sato, Mitsunobu ^a,b  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b Second Department of Oral and Maxillofacial Surgery   (Japan)

^c Department of Oral Pathology ^*

Author keywords

Acinar tissue; Cepharanthin; Matrix metalloproteinase 9; Nuclear factor B; Sj gren's syndrome; Type IV collagen

Indexed keywords

ALKALOID; BISCOCLAURINE ALKALOID; CEPHARANTHINE; COLLAGEN TYPE 4; GELATINASE B; I KAPPA B ALPHA; PHOSPHOPROTEIN; SYNAPTOTAGMIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ACINAR CELL; ACINAR TISSUE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INDUCTION; FEMALE; HISTOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; INFLAMMATION; LACRIMAL GLAND; MONONUCLEAR CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SALIVARY GLAND; SIGNAL TRANSDUCTION; SJOEGREN SYNDROME; THYMECTOMY; TISSUE INJURY;

ALKALOIDS; ANIMALS; APOPTOSIS; CARRIER PROTEINS; COLLAGEN TYPE IV; FEMALE; I-KAPPA B PROTEINS; IMMUNOHISTOCHEMISTRY; LACRIMAL APPARATUS; MATRIX METALLOPROTEINASE 9; MICE; MICE, MUTANT STRAINS; NEOPLASM PROTEINS; SALIVARY GLANDS; SJOGREN'S SYNDROME;

EID: 33646450400     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Alspaugh MA, Whaley WW, Wohl MJ, Bunin JJ. Sjögren's syndrome. In: Kelley WN, Harris ED Jr, Ruddy S, Sledge CB, editors. Textbook of rheumatology. Philadelphia: WB Saunders; 1981:971-99.
2. Daniel TE. Labial salivary gland biopsy in Sjögren's syndrome: Assessment as a diagnostic criterion in 362 suspected cases. Arthritis Rheum 1984;27:147-56.
3. Hamano H, Saito I, Haneji N, Mitsuhashi Y, Miyasaka N, Hayashi Y. Expression of cytokine genes during development of autoimmune sialadenitis in MRL/lpr mice. Eur J Immunol 1993;23:2387-91.
4. Fox RI, Kang H-I, Ando D, Abrams J, Pisa E. Cytokine mRNA expression in salivary gland biopsies of Sjögren's syndrome. J Immunol 1994;152:5532-9.
5. Bernfield M, Banerjee SD, Cohn RH. Dependence of salivary epithelial morphology and branching morphogenesis upon acid mucopolysaccharide protein (proteoglycan) at the epithelial surface. J Cell Biol 1972;52:674-89.
6. 2 production by synovial cells and dermal fibroblasts. J Exp Med 1985;162:2163-8.
7. Goldring MB, Birkhead JR, Suen L-F, et al. Interleukin-1β-modulated gene expression in immortalized human chondrocytes. J Clin Invest 1994;94:2307-16.
8. Konttinen YT, Kangaspunta P. Lindy O, et al. Collagenase in Sjögren's syndrome. Ann Rheum Dis 1994;53:836-9.
9. Hanemaaijer R, Visser H, Konttinen YT, Koolwijk P, Verheijen JH. A novel and simple immunocapture assay for determination of gelatinase-B (MMP-9) activities in biological fluids: saliva from patients with Sjögren's syndrome contains increased latent and active gelatinase-B levels. Matrix Biol 1998;17:657-65.
10. Konttinen YT, Halinen S, Hanemaaijer R, et al. Matrix metalloproteinase (MMP)-9 type IV collagenase/gelatinase implicated in the pathogenesis of Sjögren's syndrome. Matrix Biol 1998; 17:335-47.
11. Azuma M, Aota K, Tamatani T, et al. Suppression of TNF-α-induced MMP-9 production by the introduction of a super-repressor form of IκBα cDNA into immortalized human salivary gland acinar cells: prevention of the destruction of the acinar structure in Sjögren's syndrome salivary glands. Arthritis Rheum 2000;43:1756-67.
12. Azuma M, Aota K, Tamatani T, et al. Suppression of TNF-α-induced MMP-9 production in human salivary gland acinar cells by cepharanthine occurs via downregulation of NF-κB: a possible therapeutic agent for preventing the destruction of the acinar structure in the salivary glands of Sjögren's syndrome patients. Arthritis Rheum 2002;46:1585-94.
13. Hayashi Y, Kojima A, Hata M, Hirokawa K. A new mutation involving the sublingual gland in NFS/N mice: partially arrested mucous cell differentiation. Am J Pathol 1988;132:187-91.
14. Haneji N, Hamano H. Yanagi K, Hayashi Y. A new animal model for primary Sjögren's syndrome in NFS/sld mutant mice. J Immunol 1994;153:2769-77.
15. White SC, Casarett GW. Induction of experimental autoallergic sialadenitis. J Immunol 1974;112:178-85.
16. Greenspan JS, Daniels TE, Talal N, Silvester RA. The histopathology of Sjögren's syndrome in labial salivary gland biopsies. Oral Surg 1974;37:217-29.
17. Chisholm D, Mason D. Labial salivary gland biopsy in Sjögren's disease. J Clin Pathol 1968;21:656-60.
18. Chen Z, Hagler J, Palombella VJ, et al. Signal-induced site-specific phosphorylation targets IκBα to the ubiquitin-proteasome pathway. Genes Dev 1995;9:1586-97.
19. Yamamoto Y, Gaynor RB. IκB kinases: key regulators of the NF-κB pathway. Trends Biochem Sci 2004;29:72-9.
20. Aoudjit F, Vuori K. Matrix attachment regulates Fas-induced apoptosis in endothelial cells: a role for c-Flip and implication for anoikis. J Cell Biol 2001;152:633-43.
21. Jiang C, Wang Z, Ganther H, Lu J. Caspases as key executors of methyl selenium-induced apoptosis (anoikis) of DU-145 prostate cancer cells. Cancer Res 2001;61:3062-70.
22. Okada Y, Tsuchiya H, Shimizu H, et al. Induction and stimulation of 92-kDa gelatinase/type IV collagenase production in osteosarcoma and fibrosarcoma cell lines by tumor necrosis factor a. Biochem Biophys Res Commun 1990;17:610-7.
23. Sato H, Seiki M. Regulatory mechanism of 92 kDa type IV collagenase gene expression which is associated with invasiveness of tumor cells. Oncogene 1993;8:395-405.
24. Mazzieri R, Masiero L, Zanetta L, et al. Control of type IV collagenase activity by components of the urokinase-plasmin system: a regulatory mechanism with cell-bound restraints. EMBO J 1997;16:2319-32.
25. Sorsa T, Salo T, Koivunen E, et al. Activation of type IV procollagens by human tumor-associated trypsin-2. J Biol Chem 1997;272:21067-74.
26. Meredith JE Jr, Fazeli B, Schwartz MA. The extracellular matrix as a cell survival factor. Mol Cell Biol 1993;4:953-61.
27. Frisch SM, Ruoslahti E. Integrins and anoikis. Curr Opin Cell Biol 1997;9:701-6.
28. Frisch SM, Francis H. Disruption of epithelial cell-matrix interactions induces apoptosis. J Cell Biol 1994;124:619-26.
29. Gutterman JU, Fien S, Quesada J, et al. Recombinant leukocyte A interferon: pharmacokinetics, single-dose tolerance, and biologic effects in cancer patients. Ann Intern Med 1982;96:549-56.
30. Hamburger AW, Salmon SE. Primary bioassay of human tumor stem cells. Science 1977;197:461-3.
31. Havell EA, Vilcek J. Inhibition of interferon secretion by vinblastine. J Cell Biol 1975;64:716-9.
32. Ono M. Antitumor effect of cepharanthin: activation of regional lymph node lymphocytes by intratumoral administration. Clin Immunol 1987;19:1061-4.
33. Morioka S, Ono M. Tanaka N, Orita K. Synergistic activation of rat alveolar macrophages by cepharanthin and OK-432. Jpn J Cancer Chemother 1985;12:1470-5.
34. Yamamoto Y, Yin M-J, Lin K-M, Gaynor RB. Sulindac inhibits activation of the NF-κB pathway. J Biol Chem 1999;274:27307-14.
35. Steinfeld SD, Demols P, Appelboom T. Infliximab in primary Sjögren's syndrome. Arthritis Rheum 2002;46:3301-3.
36. Mariette X, Ravaud P, Steinfeld S, et al. Inefficacy of infliximab in primary Sjögren's syndrome. Arthritis Rheum 2004;50:1270-6.